<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38333462</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Long-Lasting SARS-CoV-2 Infection With Post-COVID-19 Chronic Interstitial Pneumonia in a Patient With Chronic Lymphocytic Leukemia Treated Successfully With Intravenous Immunoglobulin.</ArticleTitle><Pagination><StartPage>e51890</StartPage><MedlinePgn>e51890</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e51890</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.51890</ELocationID><Abstract><AbstractText>Post-coronavirus disease 2019 (post-COVID-19) condition is a post-acute syndrome characterized by non-specific symptoms that remain for at least two months and typically appear three months after the start of the acute phase. Individuals with chronic lymphocytic leukemia (CLL) are considered to be at high risk of contracting COVID-19. It is also becoming increasingly evident that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response is frequently lacking or insufficient. We present a 77-year-old male patient with CLL who had multiple hospitalizations for the management of pneumonia related to persistent COVID-19 infection due to hypogammaglobulinemia. He was subsequently treated with intravenous immunoglobulin (IVIG). This case emphasizes the importance of the early detection of hypogammaglobulinemia in patients with CLL and long COVID because of the potential therapeutic benefit of IVIG therapy. We also provide a literature review on COVID-19 infection in CLL patients, focusing mainly on the subset population of patients with hypergammaglobulinemia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024, Haddad et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haddad</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Internal Medicine, Saint Michael's Medical Center, Newark, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Maharmeh</LastName><ForeName>Qusai</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Internal Medicine, Saint Michael's Medical Center, Newark, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kloub</LastName><ForeName>Mohammad N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Internal Medicine, Saint Michael's Medical Center, Newark, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Elrazi A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Internal Medicine, One Brooklyn Health/Interfaith Medical Center, Brooklyn, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaaban</LastName><ForeName>Hamid</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Hematology/Oncology, Saint Michael's Medical Center, Newark, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chronic lymphocytic leukemia (cll)</Keyword><Keyword MajorTopicYN="N">covid-19 in cancer patients</Keyword><Keyword MajorTopicYN="N">intravenous immunoglobulin</Keyword><Keyword MajorTopicYN="N">non-specific interstitial pneumonia</Keyword><Keyword MajorTopicYN="N">sars-cov-2 and covid-19</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>9</Day><Hour>4</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38333462</ArticleId><ArticleId IdType="pmc">PMC10851034</ArticleId><ArticleId IdType="doi">10.7759/cureus.51890</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Epidemiology and clinical presentation of COVID-19 in older adults. Abul Y, Leeder C, Gravenstein S. Infect Dis Clin North Am. 2023;37:1&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9633621</ArticleId><ArticleId IdType="pubmed">36805007</ArticleId></ArticleIdList></Reference><Reference><Citation>Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. Blixt L, Bogdanovic G, Buggert M, et al. Leukemia. 2022;36:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8475381</ArticleId><ArticleId IdType="pubmed">34564699</ArticleId></ArticleIdList></Reference><Reference><Citation>Recurrent and persistent respiratory tract viral infections in patients with primary hypogammaglobulinemia. Kainulainen L, Vuorinen T, Rantakokko-Jalava K, Osterback R, Ruuskanen O. J Allergy Clin Immunol. 2010;126:120&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112312</ArticleId><ArticleId IdType="pubmed">20541246</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Director-General's Remarks at the Media Briefing on 2019-nCoV on 11 February 2020.  [
Feb;
2020 
];https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 2020 2019:11.</Citation></Reference><Reference><Citation>World Health Organization.(2023, December December, 19 19. WHO COVID-19 Dashboard.  [
Dec;
2023 
]. 2023. https://data.who.int/dashboards/covid19/cases?n=c https://data.who.int/dashboards/covid19/cases?n=c</Citation></Reference><Reference><Citation>Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data. Giannakoulis VG, Papoutsi E, Siempos II. JCO Glob Oncol. 2020;6:799&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7328119</ArticleId><ArticleId IdType="pubmed">32511066</ArticleId></ArticleIdList></Reference><Reference><Citation>Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Ann Intern Med. 2021;174:69&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7505025</ArticleId><ArticleId IdType="pubmed">32941052</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Zhou F, Yu T, Du R, et al. Lancet. 2020;395:1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer and risk of COVID-19 through a general community survey. Lee KA, Ma W, Sikavi DR, et al. Oncologist. 2021;26:0&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460944</ArticleId><ArticleId IdType="pubmed">32845538</ArticleId></ArticleIdList></Reference><Reference><Citation>Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Dai M, Liu D, Liu M, et al. Cancer Discov. 2020;10:783&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309152</ArticleId><ArticleId IdType="pubmed">32345594</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group. &#x160;imkovi&#x10d; M, Turcs&#xe1;nyi P, &#x160;pa&#x10d;ek M, et al. Ann Hematol. 2023;102:811&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9969021</ArticleId><ArticleId IdType="pubmed">36847805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Parikh SA, Leis JF, Chaffee KG, et al. Cancer. 2015;121:2883&#x2013;2891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545721</ArticleId><ArticleId IdType="pubmed">25931291</ArticleId></ArticleIdList></Reference><Reference><Citation>Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Morrison VA. Clin Lymphoma Myeloma. 2009;9:365&#x2013;370.</Citation><ArticleIdList><ArticleId IdType="pubmed">19858055</ArticleId></ArticleIdList></Reference><Reference><Citation>Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Cooper N, Davies EG, Thrasher AJ. Br J Haematol. 2009;146:120&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">19438506</ArticleId></ArticleIdList></Reference><Reference><Citation>People Who Are Immunocompromised.  [
Jun;
2023 
]. 2023. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-who-are-immunocompromised.html https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-who-are-immunocompromised.html</Citation></Reference><Reference><Citation>Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Casulo C, Maragulia J, Zelenetz AD. Clin Lymphoma Myeloma Leuk. 2013;13:106&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4035033</ArticleId><ArticleId IdType="pubmed">23276889</ArticleId></ArticleIdList></Reference><Reference><Citation>Safety and efficacy of antiviral drugs for the treatment of COVID-19: a systematic review. Nie Z, Sun T, Zhao F. Infect Drug Resist. 2022;15:4457&#x2013;4466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9381013</ArticleId><ArticleId IdType="pubmed">35983302</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Liang W, Guan W, Chen R, et al. Lancet Oncol. 2020;21:335&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159000</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>The clinical significance of hypogammaglobulinaemia and serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukaemia (CLL) Best OG, Crassini K, Freeman JA, Mulligan SP. Scand J Infect Dis. 2013;45:729.</Citation><ArticleIdList><ArticleId IdType="pubmed">23826794</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Proal AD, VanElzakker MB. Front Microbiol. 2021;12:698169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>